- Home
- BXP vs FMS Comparison
BXP vs FMS Comparison
Compare BXP & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXP | FMS |
|---|---|---|
| Founded | 1970 | 1996 |
| Country | United States | Germany |
| Employees | N/A | 108165 |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 12.5B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | BXP | FMS |
|---|---|---|
| Price | $69.65 | $24.18 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 18 | 2 |
| Target Price | ★ $71.94 | $30.00 |
| AVG Volume (30 Days) | ★ 1.5M | 597.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.86% | 2.57% |
| EPS Growth | ★ 1833.33 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $3,482,279,000.00 | N/A |
| Revenue This Year | $11.00 | N/A |
| Revenue Next Year | $2.91 | $3.83 |
| P/E Ratio | $109.53 | ★ $15.62 |
| Revenue Growth | ★ 2.19 | N/A |
| 52 Week Low | $49.93 | $20.02 |
| 52 Week High | $79.33 | $27.64 |
Technical Indicators
Market Signals| Indicator | BXP | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 64.77 |
| Support Level | $68.44 | $22.50 |
| Resistance Level | $72.84 | $24.71 |
| Average True Range (ATR) | 1.59 | 0.35 |
| MACD | 0.28 | 0.04 |
| Stochastic Oscillator | 89.92 | 88.67 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP owns 179 properties consisting of approximately 52.6 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.